EMA Authorised: Kyprolis (carfilzomib) — Amgen Europe B.V.

View source ↗

Summary

The European Medicines Agency authorised Kyprolis (carfilzomib) for the treatment of multiple myeloma. The decision was made on 14 December 2023 under accelerat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Kyprolis (carfilzomib)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Amgen Europe B.V.. Decision date: 14/12/2023. Accelerated assessment